T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia.
In chronic myeloid leukaemia (CML), peptides from the fusion region of bcr3/abl2 are likely to play a role in anti-leukaemic T cell immunity. We investigated whether T cells that recognize bcr/abl fusion peptides could be detected in healthy donors and CML patients. T cell responses against bcr3/abl2 fusion peptides were analysed by gamma-interferon enzyme-linked immunospot assays after prestimulation of peripheral blood mononuclear cells in the presence of anti-CD3-antibodies and interleukin-2. Our results suggest that the T cell repertoire contains bcr3/abl2-reactive T cells in CML patients who are in cytogenetic remission, but also in some healthy individuals.
Westermann
Jörg
J
Department of Haematology and Oncology, Charité, University Medicine Berlin, Campus Virchow Clinic, Augustenburger Platz 1, 13353 Berlin, Germany. joerg.westermann@charite.de
Schlimper
Claudia
C
Richter
Günther
G
Mohm
Johannes
J
Dörken
Bernd
B
Pezzutto
Antonio
A
D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D016044:Fusion Proteins, bcr-abl / Q000276:immunology*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
D016044:Fusion Proteins, bcr-abl